Summary: This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis; trained in pulmonary medicine at Massachusetts General Hospital with additional research training at Boston University School of Medicine. His principal academic appointment is as associate professor of medicine, Harvard Medical School, with secondary parallel appointments in the Department of Global Health and Social Medicine and Harvard School of Public Health. In 2002 he joined Partners In Health as Director of Tuberculosis Research.
His research interests include the control of multidrug-resistant tuberculosis (MDR-TB) in Peru, Russia, and other high-burden countries, with a special research interest in airborne TB transmission and control. Dr. Nardell is currently conducting a research project in South Africa studying the transmission of MDR-TB using large numbers of guinea pigs to quantify the infectiousness of MDR-TB patients and the effectiveness of various control interventions, including ultraviolet germicidal irradiation. (Click here to view full bio) During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus.
Additional TB R&D News:
CDC: Latent TB treatment may now be done in 3 months
Metabolite-enabled eradication of bacterial persisters by aminoglycosides